




2nd CONGRESS ON

TRANSLATIONAL RESEARCH IN HNSCC: NEW CHALLENGES FOR FUTURE THERAPIES

November 24th-25th 2025

Organizers:

Dr. David Virós

Head of the department of otorhinolaryngology Vall d'Hebron Hospital (HUVH).
Co-director of the Head and Neck group: Biomedical Research in Cancer Stem Cells, Vall d'Hebron Research Institute (VHIR).

Dr. Matilde E. Lleonart

Co-director of the Head and Neck group: Biomedical Research in Cancer Stem Cells, VHIR.

SUMMARY

Head and neck cancer is an understudied disease with a high relapse and mortality rate. Therapeutic modalities have not significantly improved since the last 40 years. Even though immunotherapy is providing promising results, currently it is only applicable to metastatic patients. Finding new therapies for HNSCC patients is the main objective and challenge for basic and clinical researchers. With the idea of promoting new challenges and future applications for medium term applicability to HNSCC patients, the Vall d'Hebron Hospital (HUVH) will organize a translational and clinical research conference on 24th and 25th November 2025.

REGISTRATION FREE

Registration fee - **100€**

Includes: Theoretical lectures, coffee breaks and lunches

Web site: <https://www.vallhebron.com/docencia/aula/agenda-cientifica/translational-research-hnsc-new-challenges-future-therapies-0>

ACCREDITATION

The certificate will be given to attendees who meet a minimum of 80% attendance.

VENUE

Edifici Central de Recerca (Nou edifici).

Vall d'Hebron Research Institute (VHIR).

Pg. Vall d'Hebron 119-129 Barcelona

WITH THE SCIENTIFIC ENDORSEMENT OF



El aval de Fundación Española TTCC no implica la organización ni financiación del evento

WITH THE SUPPORT OF



SPONSORS



TECHNICAL SECRETARY

Aula Vall d'Hebron - Technical Secretariat for External Training Activities –

inscripciones@aulavallhebron.cat – 693785436



Aula Vall d'Hebron - Secretaría Técnica actividades formativas externas –

inscripciones@aulavallhebron.cat - 693785436

24TH Nov

- 09.00 - 09.30** Delivery of documentation and presentation.
- 09.30 - 10.00** Liquid biopsy in the diagnosis, prognosis, and monitoring of patients diagnosed with HPV-related oropharyngeal cancer. *Laia Alemany (Head of the Cancer Epidemiology Research Programme. (Catalan Institute of Oncology/IDIBELL, Barcelona).*
- 10.00 - 10.30** New targeted therapies against EGFR - bispecific antibodies.
Katerin Rojas (Medical Oncologist, Head and Neck Tumor Unit – Early Drug Development Unit, HUVH).
- 10.30 - 11.00** Biomarker discovery through drug screening and genomic profiling of HPV-negative head and neck cancers. *Outi Monni (Applied Tumor Genomics Research Program, Faculty of Medicine and Institute for Molecular Medicine Finland, University of Helsinki).*
- 11.00 - 11.30** Screening of oral lesions using cytology in patients with Fanconi Anemia.
Alba de Pablo (Clinical researcher, Vall d'Hebron Universitary Hospital).
- 11.30 - 12.00** **Coffee break**
- 12.00 - 12.30** Targeting CDK4/6 Enhances Chemotherapy Response in Head and Neck Squamous Cell Carcinoma.
Mónica Álvarez (Cancer Research Center, University of Salamanca, CSIC).
- 12.30 - 13.00** Perioperative immunotherapy treatment in squamous cell carcinoma – clinical and translational data.
Irene Braña (Medical oncologist, Head of the Head and Neck Cancer Tumor Unit, HUVH).
- 13.00 – 13.30** Outsmarting Relapse in High-Risk LA-HNSCC: Nivolumab and Pembrolizumab Redefine Surgical Strategy. *Ricard Mesía (Head of the Medical Oncology Department, Institut Català d'Oncologia-Badalona).*
- 13.30 – 14.00** CDK7 in HNSCC. *Francisco Hermida (Researcher at the Foundation for Biomedical Research and Innovation of Asturias, Oviedo.).*
- 14.00– 15.00** **Lunch break**
- 15.00– 15.30** Melatonin overcomes resistance to chemotherapy associated with the overexpression of the ATP-driven transmembrane efflux pumps in head and neck cancer.
Germaine Escames Rosa (Professor of Physiology Biomedical Research Centre, University of Granada).
- 15.30 – 16.00** Saliva and Recurrence in Head and Neck Cancer: Insights from the Functional Microbiom. *Francesc Xavier Avilés (Clinical researcher at the Otorhinolaryngology Department, Hospital Clínic of Barcelona).*
- 16.00 – 16.30** Targeting the YAP/TAZ-TEAD pathway in HNSCC.
Corina Lorz (Researcher at the Health Research Institute, 12 de Octubre Hospital, Madrid).
- 16.30 – 17.00** Prognostic significance of surgical margins in laryngeal cancer treated by transoral laser microsurgery.
Armando De Virgilio (Assistant Profesor at the Sapienza Università di Roma, Italy).
- 17.00– 17.30** **Coffee break**
- 17.30 – 18.00** Exploiting Head and Neck Cancer Oncosignaling Circuitries in the Era of Precision Medicine: Novel Multimodal Targeted and Immunotherapies.
Silvio Gutkind (Distinguished Professor and Chair, Department of Pharmacology, School of Medicine, Associate Director of Basic Science, Moores Cancer Center, UC San Diego).

25TH Nov

- 09.00 - 09.30** Delivery of documentation and presentation
- 09.30 – 10.00** De-escalation Strategies in HPV-positive Oropharyngeal Cancer: Current Evidence and Future. *David Virós Porcuna (Head of Otorhinolaryngology Department HUVH).*
- 10.00 – 10.30** Involvement of 14-3-3 σ in cisplatin resistance and oncogenesis in HNSCC. *Marina Bataller (Researcher of the Head and Neck cancer group: Biomedical Research in Cancer Stem Cells, VHIR).*
- 10.30 – 11.00** Modeling of Oral Cancer in Patients with Fanconi Anemia: New Tools for New Treatments. *Ramón García Escudero (Senior researcher at the Autònoma's University of Madrid).*
- 11.00 – 11.30** Clinical development of the therapeutic HPV vaccine for HPV plus OPC. *Caroline Even (Medical Oncologist, Head of the Head and Neck Medical Oncology Unit, Institut Gustave Roussy, France).*
- 11.30 – 12.00** **Coffee break**
- 12.00 – 12.30** New compounds targeting head and neck squamous cell carcinoma based on TSPAN1 inhibition. *Matilde E. LLeonart Co-director of the Head and Neck group: Biomedical Research in Cancer Stem Cells, VHIR)*
- 12.30 – 13.00** Clinical Utility of Liquid Biopsy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Insights from the Prospective STING Study. *Filippo G. Dall'Olio (Medical Oncologist of the Head and Neck Medical Oncology Unit, Institut Gustave Roussy, France).*
- 13.00 – 13.30** Opportunities and Challenges in Building a Translational Research Group in Head and Neck Cancer. *Pablo Vergés (Clinical researcher, Otorhinolaryngology Department HUVH).*
- 13.30 – 14.30** HNSCC in Fanconi anemia young adults: genetics and therapeutic research towards the AFAN clinical trial. *Jordi Surralles (Director, Institut de Recerca Sant Pau, Hospital de Sant Pau and Full Prof of Genetics, Universitat Autònoma de Barcelona, Barcelona, Spain.)*
- 13.30 – 14.30** **Lunch break**
- 14:30 – 17:00** Thematic round tables
- Development of novel drugs for the clinic
 - Advances in immunotherapy
 - Biomarkers identification for early HNSCC detection